The Antipsychotics Market Insight & Analysis 2008

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Introduction

• 2.1 Antipsychotics Overview
• 2.2 Schizophrenia
  • 2.2.1 Classic Symptoms of Schizophrenia
  • 2.2.2 Diagnosis of Schizophrenia
  • 2.2.3 Epidemiology of Schizophrenia
  • 2.2.4 Causes and Physiological Characteristics of Schizophrenia
• 2.3 Bipolar Disorder
  • 2.3.1 Symptoms of Bipolar Disorder
  • 2.3.2 Causes of Bipolar Disorder
  • 2.3.3 Diagnosis of Bipolar Disorder
• 2.4 Antipsychotic Drugs
• 2.5 Mechanisms of the Newer Therapeutic Agents - The Atypical Antipsychotics
• 2.6 An Overview of How the Typical Antipsychotic Drugs Differ from the Atypical Antipsychotics
• 2.7 Off-Label Prescription Extending Approved Indications for Atypical Antipsychotic Drugs
• 2.8 The Prospects for Patients

Chapter 3 The World Antipsychotic Drug Market, 2006-2012

• 3.1 The Antipsychotic Market Contains Four Major Blockbusters and Set For a Fifth
• 3.2 Despite Five Major Blockbuster Drugs, the Antipsychotic Market Will Decline in Growth
• 3.3 Zyprexa Will Show Negative Growth Due to Weight Gain Problems and Patent Expiration
• 3.4 Risperdal Faces Generic Threat
• 3.5 Seroquel Shows Strong Growth - But Will it Last?
• 3.6 Abilify Will Remain a Strong Contender
• 3.7 Zeldox/Geodon Set to Reach Blockbuster Status
• 3.8 Can Leponex/Clozaril "Re-Invent" itself to Offset Decline?
• 3.9 Zyprexa Will Lose Market Leadership to Seroquel
• 3.10 Eli Lilly Currently Leads the Antipsychotic Drug Market
• 3.11 Market Expansion
• 3.12 Comparative Studies on Antipsychotic Drugs - A Blessing or a Curse for the Market Leaders?
• 3.13 The Antipsychotic Market 2006-2012: Conclusions

Chapter 4 An Analysis of Factors that Influence the Antipsychotic Market

• 4.1 SWOT Analysis of the Antipsychotic Market
• 4.2 What Are the Main Drivers, Strengths and Opportunities in the Antipsychotic Market?
• 4.3 The Atypical Antipsychotics Constitute a Large Market
• 4.4 There is Scope for Greater Penetration into Related Markets
• 4.5 Advances in Technology Likely to Bring Benefits to the Market
• 4.6 Comparative Studies - a Two Edged Sword
• 4.7 The Principal Restraints in the Antipsychotic Market
• 4.8 Patent Expiry Among the Leading Antipsychotic Drugs - An Increasing Threat
• 4.9 Risk of Diabetes and Other Serious Side Effects with the Atypical Antipsychotic Drugs
• 4.10 Breaking the Prescribing Habit for Off-Label Use of Antipsychotics
• 4.11 Concerns Over the High Price of the Treatments - Who Yields the Power?
• 4.12 A Discussion of Generic Drugs in This Market - How Great is Their Threat?

Chapter 5 A Geographical Breakdown of the World Antipsychotics Market & Major Companies Involved

• 5.1 Antipsychotics - A World Market Led by US Sales
• 5.2 The US and Europe are the Most Important Markets for Antipsychotic Drugs

Chapter 6 An Analysis of Unmet Needs in the Antipsychotics Market

• 6.1 Analysing Efficacy, Safety and Tolerability in the Antipsychotics Market via Perceptual Mapping
• 6.2 How Much Scope is There to Improve Efficacy in Antipsychotic Drugs?
• 6.3 How Much Scope is There to Improve Safety and Tolerability in Antipsychotic Drugs?
• 6.4 Pricing of the Atypical Antipsychotics - Close Scrutiny by Medical Authorities and Concern Amongst Patients' Groups
• 6.5 Screening and Diagnosis by Healthcare Services is a Necessary Pre-requisite for Market Growth
• 6.6 Direct-to-Consumer Advertising - An Opportunity to Educate Consumers but also a Source of Controversy

Chapter 7 Pipeline Drugs for Antipsychotics

• 7.1 Agents in Phase II of Clinical Development
  • 7.1.1 GSK' s 742457 and 773812
  • 7.1.2 GSK' s Talnetant
  • 7.1.3 BL-1020 from Bioline Rx
  • 7.1.4 Memory' s MEM 3454 and MEM 1003
  • 7.1.5 Richter' s RGH-188
  • 7.1.6 Eli Lilly' s LY2140023
  • 7.1.7 All Agents in Phase II development
• 7.2 Agents in Phase III of Clinical Development
  • 7.2.1 ACADIA' s Pimavanserin
  • 7.2.2 Novartis' s Licarbazepine
• 7.3 Agents in Pre-Registration
  • 7.3.1 Iloperidone
  • 7.3.2 Asenapine (ORG 5222)
  • 7.3.3 Bifeprunox
  • 7.3.4 Blonanserin
• 7.4 Summary of All Pipeline Agents from Phase II and above
• 7.5 An Overall Assessment of Pipeline Developments for the Antipsychotics Market

Chapter 8 Conclusions: the Antipsychotics Market Will Face Decreasing Growth

List of Tables

• Table 1.1 Leading Antipsychotic Drugs, 2006
• Table 2.1 First Generation Antipsychotic Drugs for Treating Schizophrenia (the Typical Antipsychotics)
• Table 2.2 Mild and Serious Side Effects of First Generation Antipyshcotics
• Table 2.3 Second Generation Antipsychotic Drugs for Treating Schizophrenia (the Atypical Antipsychotics)
• Table 2.4 Mild and Serious Side Effects of Second Generation Antipyshcotics
• Table 2.5 Top Antipsychotic Product Revenues ($m) and Market Share (%), 2006
• Table 3.1 The Leading Drugs for Treating Schizophrenia: Indications and Marketed Country/Region, 2007
• Table 3.2 World Revenues ($m) for the Leading Antipsychotic Drugs 2006-2012
• Table 3.3 World Revenues for Antipsychotic Drugs 2006 and 2012 Compared
• Table 3.4 The Global Market Share (%) by Revenue for Antipsychotic Drugs, 2006, 2009 and 2012
• Table 3.5 Top 10 Leading Companies in the Antipsychotic Drug Market, Revenue and Market Share, 2006
• Table 3.6 The Relative Strengths and Weaknesses of the Leading Schizophrenia Drugs with a Prediction of their Future Sales Potential
• Table 4.1 A SWOT Chart for the Antipsychotic Market
• Table 4.2 A Comparison of the Leading Antipsychotic Drugs' Side Effect Profiles
• Table 5.1 A Breakdown of the Antipsychotics Market by Country in 2006
• Table 5.2 Regional Breakdown of Antipsychotic Sales ($m) and Market Share (%), 2006
• Table 6.1 Efficacy and Side Effect Profiles of the Leading Antipsychotic Drugs
• Table 7.1 Antipsychotic Drugs in Phase II Clinical Trials in 2007
• Table 7.2 Summary of All Pipeline Products Phase II and Above, 2007
• Table 8.1 The Leading Antipsychotic Drugs, Revenue ($m) and Market Share (%), 2006

List of Figures

• Figure 3.1 Total World Revenues ($m) for the Antipsychotic Market 2006-2012
• Figure 3.2 World Antipsychotic Market Revenues ($m) by Drug, 2006-2012
• Figure 3.3 World Revenue Forecast ($m) for Zyprexa 2006-2012
• Figure 3.4 World Revenue Forecast ($m) for Risperdal 2006-2012
• Figure 3.5 World Revenue Forecast ($m) for Seroquel 2006-2012
• Figure 3.6 World Revenue Forecast ($m) for Abilify 2006-2012
• Figure 3.7 World Revenue Forecast ($m) for Zeldox/Geodon 2006-2012
• Figure 3.8 World Revenue Forecast ($m) for Leponex/Clozaril 2006-2012
• Figure 3.9 Market Share (%) by Revenue of Antipsychotic Drugs, 2006
• Figure 3.10 Market Share (%) by Revenue of Antipsychotic Drugs, 2009
• Figure 3.11 Market Share (%) by Revenue of Antipsychotic Drugs, 2012
• Figure 3.12 Top 10 Leading Companies in the Antipsychotic Drug Market ($m), 2006
• Figure 3.13 Leading Companies in the Antipsychotic Drug Market, Market Share (%), 2006
• Figure 5.1 Market Share (%) for Antipsychotics by Country, 2006
• Figure 5.2 Revenues ($m) for Antipsychotic Market by Country, 2006
• Figure 5.3 Regional Breakdown of the Antipsychotics Market ($m), 2006
• Figure 5.4 Regional Breakdowns of Antipsychotics, Market Share (%), 2006
• Figure 6.1 A Comparison of the Atypical Antipsychotics via Perceptual Mapping
• Figure 8.1 World Antipsychotics Market Revenue Forecast ($m) by Drug, 2006-2012

List of Companies Mentioned

• Abbott
• ACADIA
• Affectis
• Astellas
• AstraZeneca
• Banner
• BioLineRx
• BMS
• Creighton Products Corporation
• Dainippon Sumitomo
• Dr Reddy' s Laboratories
• Elbion
• Eli Lilly
• EVOTEC
• Fabre-Kramer
• Forest
• Geneva Pharmaceuticals
• GlaxoSmithKline
• Ipsen
• Johnson & Johnson
• Kohl Medical
• Lilly
• Lundbeck
• Memory
• Mylan
• NeuroSearch
• Novartis
• Noven
• Organon
• Otsuka Pharma
• Pfizer
• Roche
• Saegis
• Sanofi-aventis
• Schering-Plough
• Sobel
• Solvay
• Stem Cell Therapeutics
• Teva
• Titan
• Vanda
• Wyeth
• Zenith-Goldline